Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.
Brown, N McBain, Catherine A Nash, S Hopkins, K Sanghera, P Saran, F Phillips, M Dungey, F Clifton-Hadley, L Wanek, K
Brown, N
McBain, Catherine A
Nash, S
Hopkins, K
Sanghera, P
Saran, F
Phillips, M
Dungey, F
Clifton-Hadley, L
Wanek, K
Citations
Altmetric:
Abstract
Cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, failed to show benefit over lomustine in relapsed glioblastoma. One resistance mechanism for cediranib is up-regulation of epidermal growth factor receptor (EGFR). This study aimed to determine if dual therapy with cediranib and the oral EGFR inhibitor gefitinib improved outcome in recurrent glioblastoma.
Affiliation
Description
Date
2016
Publisher
Collections
Keywords
Type
Article
Citation
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma. 2016, 11 (5):e0156369 PLoS ONE